Filing marks milestone for Eisai's oncology R&D
This article was originally published in Scrip
Executive Summary
Eisai has made an approval filing in Switzerland for its novel anticancer agent eribulin mesylate (E7389), marking the first submission for an oncology agent developed in-house by the Japanese firm.